<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138375">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299688</url>
  </required_header>
  <id_info>
    <org_study_id>2009-12-008</org_study_id>
    <nct_id>NCT01299688</nct_id>
  </id_info>
  <brief_title>HER2 Circulating Tumor Cells in Gastric Cancer</brief_title>
  <official_title>HER2 Circulating Tumor Cells in Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to survey the frequency of HER2 (+) CTC in order to lay groundwork
      for future clinical trials incorporating Her-2 targeted agents in gastric cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future
      clinical trials incorporating Her-2 targeted agents in gastric cancer. Blood samples will be
      collected from metastatic gastric cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To survey the frequency of HER2(+) CTC in gastric cancer</measure>
    <time_frame>24month</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Gastric Cancer</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, circulating tumor cell
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        metastatic gastric cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years ② Patients with localized, histologically confirmed
             gastric cancer ③ Informed consent form

        Exclusion Criteria:

          -  No informed consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Ki Kang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 12, 2013</lastchanged_date>
  <firstreceived_date>February 17, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Won Ki Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
